Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease
详细信息    查看全文
文摘

MOG improves disease control in patients with ATLL before allo-HSCT.

MOG administration before allo-HSCT increases severe acute GVHD, leading to a high incidence of transplantation-related mortality.

Shorter intervals from the last administration of MOG to allo-HSCT were associated with the development of severe GVHD.

NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.